Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics

Drug Profile

Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics

Alternative Names: CHR-3996; Nana-val; Tractinostat; Tractinostat-Viracta-Therapeutics; Valganciclovir/Nanatinostat combination therapy - Viracta Therapeutics; VRx-3996

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Amides; Antineoplastics; Antivirals; Hypoxanthines; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Plasmablastic lymphoma; Peripheral T-cell lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma; Post-transplant lymphoproliferative disorder; Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma
  • Phase I/II Multiple myeloma; Nasopharyngeal cancer; Solid tumours
  • Phase I Cancer
  • No development reported Gastric cancer; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 09 May 2024 Japanese PMDA enables patient enrollment for nanatinostat/valganciclovir in phase II NAVAL-1 trial in Japan without previous safety and pharmacokinetics studies
  • 15 Apr 2024 Updated efficacy and adverse events data from the phase II NAVAL-1 trial in Lymphoma released by Viracta Therapeutics
  • 08 Mar 2024 Viracta Therapeutics plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO, Tablets) (NCT06302140)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top